openPR Logo
Press release

VEINTIS™ the tissue-engineered vascular graft developed by Cells for Cells, wins the 2020 National Innovation Prize

11-13-2020 10:20 AM CET | Health & Medicine

Press release from: Cells for Cells

Avonni 2020, Health category - Cells for Cells Team

Avonni 2020, Health category - Cells for Cells Team

Every year, the Avonni Prize, i.e. the Chilean National Innovation Prize and “the most important honorary recognition in Chile”, awards the most promising technologies and solutions in an effort to make visible the successful cases that are creating value through innovation in different areas and categories in the South American country.

In a year in which healthcare and biomedical-related innovations have become the center of the discussion in an effort to fight the Covid-19 pandemic, the Chilean biotech company Cells for Cells won the 2020 Avonni Prize for the R&D of Veintis™, a personalized tissue-engineered vascular graft. This year, the judging panel recognized the project´s groundbreaking innovation that included a unique bioinspired structure, a cutting-edge manufacturing process and business model.
Juan Pablo Acevedo, the Director of Cells for Cells Tissue Engineering and Biofabrication department, received the trademarked prize during a ceremony broadcasted live on National TV (TVN) on November 4th. In his words, “this award will contribute to accelerate the development of this revolutionary regenerative implant so that it can positively affect the lives of those in need in a faster and more profound way”.

The awarded technology consists of a tissue-engineered vascular graft and a rapid manufacturing robot that can personalize the implant according to the patients' requirements. The automated procedure requires less than an hour to fabricate a ready-to-transplant graft at point of care. Through this technique, the product acquires a multilayered structure that mimics the anatomy of native vasculature including intima, media and adventitia layers. Veintis™ is made of bioresorbable nanofibers that are strategically oriented to replicate mechanical responses of human vasculature, thus minimizing the chances of developing neointimal hyperplasia and thrombogenesis, considered as the current major setbacks.
In addition, the construct is compatible with stem cells incorporation that can increase the graft integration and reduce the potential risk of infection and inflammation observed in traditional alternatives (synthetic grafts). This technology combo would enable the patient’s own body to naturally restore a new blood vessel.

Recently, Veintis™ reinforced its commercial application with an IP approval in both the US and the European Union, protecting the automated manufacturing method for biofabricating tissue-engineered implants. While the Cells for Cells team received all the positive news with lot of enthusiasm, there is still much to do to reach the final goal, the patient bedside. The validation of Veintis™ through proof-of-concept in large animal studies is in process, with the support of a state grant awarded by CORFO, the Chilean national funding agency. This pre-requisite is an important milestone anticipated by the team. Cells for Cells is currently exploring new strategic commercial partnerships to accelerate the reach of its patented solution to the international market. The technology is intended to transform the way personalized implants, and tissue-engineered conduits in particular, are monetized.

Las Condes,
Santiago de Chile

About Cells for Cells S.A.

Cells for Cells is a Chilean-based biotech company dedicated to the research, development and commercialization of cell therapies and tissue-engineered solutions. Cells for Cells counts with a broad biotechnological portfolio including Cellistem®OA and Cellistem®IC, a clinical trial-supported stem cell therapy for the treatment of knee osteoarthritis and heart failure, Inkure®, a bioink for high resolution 3D bioprinting, OxiumTMExo, a culture media for the production of exosomes, and Veintis™, a bioinspired tissue-engineered vascular graft for vascular bypass applications, among others.

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release VEINTIS™ the tissue-engineered vascular graft developed by Cells for Cells, wins the 2020 National Innovation Prize here

News-ID: 2186878 • Views: 530

More Releases from Cells for Cells

Back from the dead? Advanced regenerative procedures revitalize dental pulp.
Cell therapy is advancing at a swift pace and with results recognized by the world's medical community. Improving the quality of life of patients is now possible in the area of endodontics, as recently evidenced by the randomized clinical trials and case studies published by researchers from the University of los Andes and its spinoff cell therapy biotech, Cells for Cells. Both located in Santiago, that
Cells for Cells: US patent granted for bioinspired grafts. An accelerator for th …
Santiago (Chile), 22 June 2020 – Cells for Cells, a cell therapy- and tissue engineering- focused company, announces that the U.S. Patent and Trademark Office (USPTO) has granted the company a US patent covering the AUTOMATED FABRICATION OF LAYER-BY-LAYER TISSUE ENGINEERED COMPLEX TUBES (US20180304502). The approval now legally protects this invention which details a new strategy to fabricate advanced tissue engineered conduits for diverse applications intended to treat major medical conditions